210 related articles for article (PubMed ID: 37705495)
1. PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti-PD-1 Immunotherapy.
Zheng Y; Wang Y; Lu Z; Wan J; Jiang L; Song D; Wei C; Gao C; Shi G; Zhou J; Fan J; Ke A; Zhou L; Cai J
Adv Sci (Weinh); 2023 Oct; 10(29):e2301928. PubMed ID: 37705495
[TBL] [Abstract][Full Text] [Related]
2. PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti-PD-1 immunotherapy.
Zhang D; Wang M; Wang W; Ma S; Yu W; Ren X; Sun Q
J Leukoc Biol; 2024 Mar; ():. PubMed ID: 38478709
[TBL] [Abstract][Full Text] [Related]
3. RFX6 facilitates aerobic glycolysis-mediated growth and metastasis of hepatocellular carcinoma through targeting PGAM1.
Qiu Z; Wang C; Huang P; Yuan Y; Shi Y; Lin Z; Huang Z; Zuo D; Qiu J; He W; Shen J; Niu Y; Yuan Y; Li B
Clin Transl Med; 2023 Dec; 13(12):e1511. PubMed ID: 38093528
[TBL] [Abstract][Full Text] [Related]
4. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma.
Ren F; Wu H; Lei Y; Zhang H; Liu R; Zhao Y; Chen X; Zeng D; Tong A; Chen L; Wei Y; Huang C
Mol Cancer; 2010 Apr; 9():81. PubMed ID: 20403181
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion.
Zhang D; Man D; Lu J; Jiang Y; Ding B; Su R; Tong R; Chen J; Yang B; Zheng S; Chen D; Wu J
Adv Sci (Weinh); 2023 May; 10(15):e2206669. PubMed ID: 36994647
[TBL] [Abstract][Full Text] [Related]
6. Matrine induces hepatocellular carcinoma apoptosis and represses EMT and stemness through microRNA-299-3p/PGAM1 axis.
Wang B; Wang H; Zhao Q; Lu F; Yan Z; Zhou F; Su Q
Growth Factors; 2022 Nov; 40(5-6):200-211. PubMed ID: 36260520
[TBL] [Abstract][Full Text] [Related]
7. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
10. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
11. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma.
Wen CL; Huang K; Jiang LL; Lu XX; Dai YT; Shi MM; Tang XM; Wang QB; Zhang XD; Wang PH; Li HT; Ruan XX; Wang LW; Wang XJ; Wang Q; Lu W; Xiang XQ; Sun X; Xu YH; Lai LH; Zhan Q; Li HW; Peng CH; Chen J; Huang JY; Ye DY; Chen SJ; Chen Z; Li M; Fang Y; Shen BY; Zhou L
Proc Natl Acad Sci U S A; 2019 Nov; 116(46):23264-23273. PubMed ID: 31662475
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.
Li Z; Bu J; Zhu X; Zhou H; Ren K; Chu PK; Li L; Hu X; Ding X
Biomater Adv; 2022 May; 136():212761. PubMed ID: 35929305
[TBL] [Abstract][Full Text] [Related]
13. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma.
Liu C; Miao X; Wang Y; Wen L; Cheng X; Kong D; Zhao P; Song D; Wang X; Ding X; Xia H; Wang W; Sun Q; Gong W
Cancer Sci; 2020 Oct; 111(10):3503-3515. PubMed ID: 32726482
[TBL] [Abstract][Full Text] [Related]
14. Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma.
Zhou Z; Li X; Yang G; Wang J; Li B; Huang Y; Yan J; Tao K
Theranostics; 2023; 13(10):3371-3386. PubMed ID: 37351175
[No Abstract] [Full Text] [Related]
15. SLC12A5 promotes hepatocellular carcinoma growth and ferroptosis resistance by inducing ER stress and cystine transport changes.
Tong Q; Qin W; Li ZH; Liu C; Wang ZC; Chu Y; Xu XD
Cancer Med; 2023 Apr; 12(7):8526-8541. PubMed ID: 36645171
[TBL] [Abstract][Full Text] [Related]
16. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
[TBL] [Abstract][Full Text] [Related]
17. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
[TBL] [Abstract][Full Text] [Related]
18. Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma.
Wang S; Zhu L; Li T; Lin X; Zheng Y; Xu D; Guo Y; Zhang Z; Fu Y; Wang H; Wang X; Zou T; Shen X; Zhang L; Lai N; Lu L; Qin L; Dong Q
Cell Rep Med; 2024 Feb; 5(2):101415. PubMed ID: 38382467
[TBL] [Abstract][Full Text] [Related]
19. Ferroptosis Suppressor Protein 1 Inhibition Promotes Tumor Ferroptosis and Anti-tumor Immune Responses in Liver Cancer.
Cheu JW; Lee D; Li Q; Goh CC; Bao MH; Yuen VW; Zhang MS; Yang C; Chan CY; Tse AP; Sit GF; Liu CX; Ng IO; Wong CM; Wong CC
Cell Mol Gastroenterol Hepatol; 2023; 16(1):133-159. PubMed ID: 36893885
[TBL] [Abstract][Full Text] [Related]
20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
